Abbott Laboratories (ABT)

83.81
0.11 0.13
NYSE : Health Technology
Prev Close 83.92
Open 83.81
Day Low/High 83.41 / 84.24
52 Wk Low/High 61.55 / 85.99
Volume 5.16M
Avg Volume 5.12M
Exchange NYSE
Shares Outstanding 1.76B
Market Cap 151.31B
EPS 1.30
P/E Ratio 58.35
Div & Yield 1.28 (1.41%)

Latest News

Next Week's Earnings Previews

Here are 6 companies we'll be following.

Abbott Announces FDA Approval Of The Alinity™ S System, The Latest Technology For Screening And Protecting The U.S. Blood And Plasma Supply

Abbott Announces FDA Approval Of The Alinity™ S System, The Latest Technology For Screening And Protecting The U.S. Blood And Plasma Supply

- Alinity™ s System will screen the U.S. blood and plasma supply faster and more efficiently while maintaining highest levels of accuracy

Poof: The Gloom Is Gone

We may have a few more days to get the excitement really going, but, boy, the gloom from two days ago is surely gone after Wednesday's rally.

Markets Rise on Powell's Testimony; Updates on a Few Portfolio Names

We look at Comcast, Abbott Labs and Cisco.

Video: Jim's Daily Rundown for Wednesday

Jim discusses Apple, a Comcast upgrade, Abbott Labs, and Jerome Powell's testimony.

It's Not Just the Fed: Cramer's 'Mad Money' Recap (Monday 7/8/19)

It's Not Just the Fed: Cramer's 'Mad Money' Recap (Monday 7/8/19)

Jim Cramer says investors may be misreading the Fed and the moment, but he's got your game plan for earnings season.

Starbucks, General Electric, AbbVie: 'Mad Money' Lightning Round

Starbucks, General Electric, AbbVie: 'Mad Money' Lightning Round

Jim Cramer checks in on Starbucks, General Electric, AbbVie, Adaptive Biotechnologies, Vector Group, PBF Energy and more.

Weekly Roundup

Markets set records in holiday-shortened week.

Weekly Roundup

Markets are treading water as investors ponder the G-20, politics and stress tests.

Amgen's Rally Could Just Be Getting Started

Amgen's Rally Could Just Be Getting Started

Amgen shares have rallied in recent years. Dividend growth names like Amgen remain attractive in a low-yield environment. Healthcare will likely continue in the headlines.

Nutrition Is The Missing Ingredient In Home Health Today, New Study Shows

Nutrition Is The Missing Ingredient In Home Health Today, New Study Shows

- Real-world data from Advocate Health Care and Abbott shows prioritizing nutrition care for home health patients helped keep them out of the hospital

Weekly Roundup

Stocks log gains for week on Fed rate-cut hopes and possible easing of U.S. trade tensions with China.

Abbott Hosts Conference Call For Second-Quarter Earnings

Abbott Hosts Conference Call For Second-Quarter Earnings

ABBOTT PARK, Ill., June 19, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2019 financial results on Wednesday, July 17, 2019, before the market opens.

CARE, Abbott And The Abbott Fund Launch Partnership To Address Noncommunicable Diseases (NCDs) In Humanitarian Settings

CARE, Abbott And The Abbott Fund Launch Partnership To Address Noncommunicable Diseases (NCDs) In Humanitarian Settings

- Program focused on helping people affected by conflict in Marawi City, Philippines

Abbott Launches First-ever Rapid Point-of-Care HbA1c Test To Aid In The Diagnosis Of Diabetes

Abbott Launches First-ever Rapid Point-of-Care HbA1c Test To Aid In The Diagnosis Of Diabetes

- Afinion™ HbA1c Dx test provides results in three minutes, enabling clinicians to develop informed, individualized care plans during patient consultation

Weekly Roundup

A quiet week offered a chance to get ready for volatility around the FOMC meeting and G-20 summit later this month.

Abbott Declares 382ⁿᵈ Consecutive Quarterly Dividend

Abbott Declares 382ⁿᵈ Consecutive Quarterly Dividend

ABBOTT PARK, Ill., June 14, 2019 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 32 cents per share.

New Survey Shows Millennials Can Help Avoid Blood Shortages

New Survey Shows Millennials Can Help Avoid Blood Shortages

- 45% of blood donations have historically come from people over 50 years old, but that number is declining1

New Data Show Use Of Abbott's FreeStyle® Libre System Significantly Reduces HbA1c Levels In People Living With Type 2 Diabetes

New Data Show Use Of Abbott's FreeStyle® Libre System Significantly Reduces HbA1c Levels In People Living With Type 2 Diabetes

- Presented as a late-breaker at the American Diabetes Association (ADA) 79th Scientific Sessions, new real-world data demonstrate that monitoring glucose with FreeStyle Libre System has a positive impact among adults with Type 2 Diabetes who use multiple injections of insulin daily

Weekly Roundup

Markets surge in face of multiple uncertainties.

Two Trades This Afternoon

We'll trim shares of Comcast and use that to finance a purchase in Kohl's.

Trimming a Healthcare Name for a Large Gain

We think Abbott Labs is a terrific company, but the stock already has a big premium and that may limit the potential of future gains.

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

Weekly Roundup

Rough week for stocks capped by new front in tariff wars with Mexico.

Weekly Roundup

Stocks falter on realization that trade war between U.S. and China is about more than soybeans.

TRILUMINATE Study Shows Treatment With Abbott's First-of-its-Kind Minimally Invasive Device Reduces Tricuspid Heart Valve Leaks

TRILUMINATE Study Shows Treatment With Abbott's First-of-its-Kind Minimally Invasive Device Reduces Tricuspid Heart Valve Leaks

- Late-breaking data for Abbott's investigational clip-based tricuspid heart valve repair system presented at EuroPCR

The Languishing Continues

In this market of haves and have-nots, too many stocks are still languishing and sentiment is sour -- but we're still likely oversold enough to potentially rally this week.

Rally or Selloff?: Cramer's 'Mad Money' Recap (Friday 5/17/19)

Rally or Selloff?: Cramer's 'Mad Money' Recap (Friday 5/17/19)

Jim Cramer says we'll need to pay close attention to retailers' earnings. Here's your game plan for next week.

TheStreet Quant Rating: B (Buy)